CACNA1I
ENSG00000100346
Target class
Ion channel
Chromosome
22
Approved drugs
12
Clinical candidates (approved and in development)
17
- Approved drugs
- 12
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- No
- Other names
- Cav3.3
- Target name
- CACNA1I
- Gene name
- Calcium voltage-gated channel subunit alpha1 I
- Gene symbol
- CACNA1I
- Protein name
- Voltage-dependent T-type calcium channel subunit alpha-1I (Voltage-gated calcium channel subunit alpha Cav3.3) (Ca(v)3.3)
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 18
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 18.65
- Tissue specificity (Gini)
- 0.737
- Tissue specificity (tau)
- 0.885
- KEGG gene identifiers
- hsa:8911
- Protein interaction confidence
- 0.883833
- Protein interaction partners
- 18
- R-HSA-419037
- R-HSA-445355
- End position
- 39689735
- Start position
- 39570753
- Chromosome
- 22
- Strand
- Forward
- Membrane
- Multi-pass membrane protein .
- Acrosome
- Cell Junctions
- Plasma membrane
- Tissue specificity (tau)
- 0.884547
- Expression inequality (Gini)
- 0.736862
Expression in transcripts per million
- Brain - Cerebellum
- 18.65
- Brain - Cerebellar Hemisphere
- 14.92
- Brain - Cortex
- 12.85
- Brain - Frontal Cortex (BA9)
- 10.93
- Thyroid
- 10.87
Expression in transcripts per million
- Brain - Cerebellum18.65
- Brain - Cerebellar Hemisphere14.92
- Brain - Cortex12.85
- Brain - Frontal Cortex (BA9)10.93
- Thyroid10.87
- Brain - Caudate (basal ganglia)7.42
- Brain - Nucleus accumbens (basal ganglia)6.66
- Brain - Putamen (basal ganglia)6.04
- Brain - Anterior cingulate cortex (BA24)5.89
- Brain - Hypothalamus5.38
- Brain - Hippocampus5.08
- Adrenal Gland4.41
- Brain - Amygdala3.73
- Small Intestine - Terminal Ileum3.64
- Spleen2.5
- Testis2.1
- Nerve - Tibial1.43
- Whole Blood1.24
- Lung0.89
- Brain - Spinal cord (cervical c-1)0.74
- Fallopian Tube0.71
- Stomach0.61
- Pituitary0.6
- Brain - Substantia nigra0.57
- Colon - Transverse0.51
And 29 more, listed on the interactive page.
Biological processes
- GO:0007165
Cellular components
- GO:0005886
- GO:0005245
- GO:0005515
Related records
Trials (1,035)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (20)
- Apinocaltamide Voltage-gated T-type calcium channel blocker
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Ethosuximide Voltage-gated T-type calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Methsuximide Voltage-gated T-type calcium channel blocker
- Mibefradil Voltage-gated T-type calcium channel blocker
- Mibefradil dihydrochloride Voltage-gated T-type calcium channel blocker
- Paramethadione Voltage-gated T-type calcium channel blocker
- Phensuximide Voltage-gated T-type calcium channel blocker
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Suvecaltamide Voltage-gated T-type calcium channel modulator
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker
- Trimethadione Voltage-gated T-type calcium channel blocker